First authorJournal abbreviation yearCountrySourceHPV primersNo. casesAny61116183133354556
    Snijders PJInt J Cancer 1996NetherlandsFF and PE*GP5/6728.
    Fouret PArch Otolaryngol Head Neck Surg 1997FrancePEWD72/76+WD66/67/1545817.
    Alvarez AIAm J Otolaryngol 1997SpainUnsure*TS-PCR only1921.110.510.50.0
    Hoffman MActa Otolaryngol 1998GermanyFF*MY09/11 of TS-PCR negative2326.
    Andl TCancer Res 1998GermanyFF*WD72/76+WD66/67/1543562.
    Adams VAnticancer Res 199SwitzerlandFF*MY09/11560.
    Kleist BJ Oral Pathol Med 2000GermanyPE*MY09/111216.78.38.3
    Badaracco GAnticancer Res 2000ItalyFF*MY09/11450.
    van Houten VMInt J Cancer 2001NetherlandsFFGP5+/6+3023.323.
    Mork JNEJM 2001Norway, Finland, SwedenPE*GP5+/6+ CpI/CpIIG1866.
    Klussman JPCancer 2001GermanyPE*Degenerate primers A10/A5-A6/A8; CP62/70-CP65/69a3345.
    Lindel KCancer 2001SwitzerlandPE*SPF109914.
    Szkaradkiewicz AClin Exp Med 2002PolandUnsureMY09/112810.70.00.0
    Mellin HAnticancer Res 2003SwedenPE*GP5+/6+6045.045.01.7
    Koskinen WJInt J Cancer 2003FinlandFFSPF10 FAP 59/64 CP65/70 CP66/6951000.00.01000.
    Herrero RJ Natl Cancer Inst 2003Italy, Spain, North Ireland, PolandFF*GP5+/6+8914.
    Kansky AAActa Virol 2003SloveniaPE*PGMY09/11 GP5+/6+ WD72/76+WD66/67/154450.
North America
    Paz IBCancer 1997United StatesFFMY09/11 IU/IUDO15600.053.30.0
    Schwartz SMJ Natl Cancer Inst 1998United StatesPE*MY09/115541.812.73.634.50.0
    Gillison MLJ Natl Cancer Inst 2000United StatesFF*PGMY09/116256.
    Ringstrom EClin Cancer Res 2002United StatesFF*MY09/112951.751.70.0
    Strome SEClin Cancer Res 2002United StatesPE*MY09/11 L1 6582-23D/7033-22U5246.
    Smith EMInt J Cancer 2004United StatesPE*MY09/116536.
    Herrero RJ Natl Cancer Inst 2003CanadaFF*GP5+/6+757.
    Mineta HAnticancer Res 1998JapanFFTS-PCR only1353.838.515.4
    Tsuhako KJ Oral Pathol Med 2000JapanPE*TS-PCR only1752.917.65.941.211.8
    Higa MOral Oncol 2003JapanFFTS-PCR only1250.025.08.333.316.7
    Herrero RJ Natl Cancer Inst 2003IndiaFF*GP5+/6+1225.
Other (includes Central and South America, Australia, and Africa)
    Li WInt J Cancer 2003AustraliaPE*GP5+/6+A10/A5-A6/A8 CP65/70ct-CP66/69ct6746.
    Herrero RJ Natl Cancer Inst 2003Cuba, Australia, SudanFF*GP5+/6+3417.
  • * Study assessed a human gene marker for the quality of the cancer specimen and reported results for this laboratory assessment.

  • Author provided additional data from their study for this review.